GLP1 agonists have emerged as promising therapeutic options for the treatment of obesity and type 2 diabetes in general obesity (2); however, in cases of AS the effects were only moderate with a mean weight loss of 6% (−5.4 kg) (3). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.